KZIA

Kazia Therapeutics Ltd

Add to Watchlist

Advanced Chart

7.790

-0.59(-7.041%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.310

Open

8.200

VWAP

7.91

Vol

913.43K

Mkt Cap

13.57M

Low

7.400

Amount

7.23M

EV/EBITDA(TTM)

Total Shares

29.77M

12.88M

EV/OCF(TTM)

P/S(TTM)

142.86

Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

2 Analyst Rating

79.72% Upside

Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

79.72% Upside

Current: 7.790

Low

13.00

Averages

14.00

High

15.00

79.72% Upside

Current: 7.790

Low

13.00

Averages

14.00

High

15.00

H.C. Wainwright

Sean Lee

Buy

upgrade

$2 -> $13

2025-07-10

Reason

H.C. Wainwright

Sean Lee

Price Target

$2 -> $13

2025-07-10

upgrade

Buy

Reason

H.C. Wainwright analyst Sean Lee raised the firm's price target on Kazia Therapeutics to $13 from $2 and keeps a Buy rating on the shares following the adjusted ratio of U.S. shares to 500:1 from 100:1.

Maxim Group

Jason McCarthy

Strong Buy

Initiates

2025-02-06

Reason

Maxim Group

Jason McCarthy

Price Target

2025-02-06

Initiates

Strong Buy

Reason

Maxim initiated coverage of Kazia Therapeutics with a Buy rating and $3 price target. The company's lead asset is paxalisib, a potent, oral, brain-penetrant small molecule inhibitor of PI3K and mTOR being developed as an adjuvant therapy to treat newly diagnosed unmethylated glioblastoma - GBM - multiforme, the analyst tells investors in a research note. Paxalisib has shown numerical overall survival benefits in two studies involving unmethylated GBM patients, and while the drug did not progress to the second stage after being evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment platform trial, it demonstrated consistent overall survival benefits with a prior Phase 2 study, Maxim notes, adding that Kazia is on pace to initiate a Phase 3 trial for paxalisib in the second half of this year.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kazia Therapeutics Ltd (KZIA.O) is -0.65, compared to its 5-year average forward P/E of -25.64. For a more detailed relative valuation and DCF analysis to assess Kazia Therapeutics Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-25.64

Current PE

-0.65

Overvalued PE

12.41

Undervalued PE

-63.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.02

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

10.71

Undervalued EV/EBITDA

-12.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

288.42

Current PS

253.71

Overvalued PS

1294.16

Undervalued PS

-717.32